Nature Medicine publication: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen activator receptor plasma levels: a double-blind, randomized controlled phase 3 trial An early increase of suPAR serum levels indicates [...]
NEW STUDY Elevated preoperative suPAR is a strong and independent risk marker for postoperative complications in patients undergoing major noncardiac surgery A recent prospective observational study has investigated whether suPAR [...]
NEW STUDY suPAR is associated with risk for thromboembolic complications and mortality in patients with COVID-19 Conclusion Higher suPAR levels at the time of hospital admission are associated with a higher risk for [...]
NEW STUDY Evaluation of suPAR levels in patients with COVID-19 and non-COVID-19 Pneumonia: An observational cohort study Results Among patients with chest infection who required hospitalization, suPAR was significantly higher on admission in [...]
suPAR measured using suPARnostic® TurbiLatex predicts critical illness and kidney failure in patients admitted to the intensive care unit Objective This prospective cohort study aimed to describe the role and feasibility of the prognostic [...]
suPAR: An exciting biomarker of systemic chronic inflammation. suPAR provides a more stable biomarker of systemic chronic inflammation than CRP or IL-6 and is less subject to the influence of acute infection and environmental [...]
New study: suPAR (cut-off levels ⩽4, 4-6, and ⩾6 ng/mL) can predict the need for mechanical ventilation and mortality in patients with COVID-19 symptoms. suPAR is a biomarker associated with adverse outcomes. This [...]
Measuring suPAR in COVID-19 patients presents a valuable tool for improving risk stratification accuracy and helping to predict the risk of developing severe consequences of a COVID-19 infection. This was confirmed in a newly [...]
If you have any questions regarding our products or business, write to us here
New Webinar
